# ZhenGe Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhenge-biotech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.zgbiotech.com
- Total disclosed funding: $236M
- Latest round: Series C (Aug 18, 2022)
- Investors on record: 20

## About

Based in China, founded in 2017, ZhenGe Biotech is a macromolecular biopharmaceuticals developer that focuses CDMO services for macromolecular biopharmaceuticals, development and production of mammalian cell culture media, etc. In 2018, Shanghai Zhangjiang company provided one-stop CDMO service. In 2019, Shanghai ZhenGe Biotechnology Co.,Ltd was recognized as a high-tech enterprise. In March 2020, Shanghai ZhenGe Biotechnology Co.,Ltd. completed USD 55 million of series A financing, In April 2020, Pudong Zhoupu CM C R&D and culture medium development center was established. In June 2020, Lingang Blue Bay Shanghai Zhenhao Biotechnology Co., Ltd. opened a new era of ADC business. In September 2020, Lingang Blue Bay 2000LX 3/5000LX 3 GM standard commercial production base started. In November 2020, Lingang Blue Bay 200LX 21500LX 1 GMP standard pilot production line was put into operation for 200 tons per year; GMp standard medium production line was put into operation. In February 2021, Shanghai ZhenGe Biotechnology Co. Ltd. completed series B financing. Team members of Shanghai ZhenGe Biotechnology Co.,Ltd have had developed a fed-batch culture process for antibody production, with an expression level of 14.5 g/L, which was an industry record. Later, it developed the PD-1 antibody production process for Junshi Bio, and created the record of the shortest process development cycle. The product quality is high, the expression level is high (up to 7.5 g/L), the amplification and production consistency is good, and the end cell viability is good. The high rate is an important manifestation of the advantages of Zhenge Biotechnology.

The core business of Zhenge Biology is CDMO service for macromolecular biopharmaceuticals, development and production of mammalian cell culture media including: drug-ready analysis of macromolecular drugs, CMC clinical application package for macromolecular drugs, cell line development, process development and optimization, pilot production, clinical sample production and commercial CMO services, process characterization and verification research, drug analysis Services, cell culture medium formulation development and commercial production, etc.

## Funding rounds

- Series C, Aug 18, 2022, $15M — Shanghai Zhangjiang Science & Technology Venture Capital, Sinopharm-CICC Capital, Zhangjiang Torch Investment, Lingang Lanwan Fund, Haiwang Capital
- Series C, Jan 11, 2022, $100M — Sofina, Novo Holdings, Qiming Venture Partners, IDG Capital, Cowin Capital, Goldman Sachs Asset Management, LYFE Capital, Ningxia Junxin Venture Capital Co., Ltd., GT Capital
- Series B, Mar 22, 2021, $70M — Qiming Venture Partners, IDG Capital, CASH Capital, CMB International Asset Management, LYFE Capital, Ningxia Junxin Venture Capital Co., Ltd., Hangzhou Fuzhuo Venture Capital, Shanghai Growth Investment, GP Capital Advisory
- Series A, Mar 30, 2020, $51M — IDG Capital, Cowin Capital, Korea Investment Partners, LYFE Capital, Ningxia Junxin Venture Capital Co., Ltd., Shanghai Growth Investment

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B, Series C
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A, Series C
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- LYFE Capital — Series A, Series B, Series C
- Ningxia Junxin Venture Capital Co., Ltd. — Series A, Series B, Series C
- Shanghai Growth Investment (https://capitalatlas.ai/funds/shanghai-growth-investment) — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- Hangzhou Fuzhuo Venture Capital (https://capitalatlas.ai/funds/hangzhou-fuzhuo-venture-capital) — Series B
- GP Capital Advisory — Series B
- Sofina — Series C
- Novo Holdings — Series C
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- GT Capital (https://capitalatlas.ai/funds/gt-capital) — Series C
- Shanghai Zhangjiang Science & Technology Venture Capital — Series C
- Sinopharm-CICC Capital (https://capitalatlas.ai/funds/sinopharm-cicc-capital) — Series C
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series C
- Lingang Lanwan Fund — Series C
- Haiwang Capital (https://capitalatlas.ai/funds/haiwang-capital) — Series C